SRPT — Sarepta Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.88bn
- $1.94bn
- $2.20bn
Acting US FDA chief meets with rare disease groups to mend fences
Sarepta falls on lower quarterly sales for gene therapy
Sarepta Therapeutics Q1 revenue falls on lower ELEVIDYS sales
US FDA's accelerated approval for drugs needs more transparency, says research firm (updated)
US FDA's accelerated approval for drugs needs more transparency, says research firm
Roche launches new Elevidys study after feedback from European regulator
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
Brief: Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1
Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials
Brief: Sarepta Announces That Screening And Enrollment Are Underway In Endeavor Cohort 8 To Evaluate Enhanced Immunosuppression Regimen As Part Of Elevidys Gene Therapy For Non-Ambulant Individuals With Duchenne
Uniqure jumps after FDA vaccines chief Vinay Prasad to step down
FDA vaccines chief Vinay Prasad to step down in April (updated)
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America
U.S. STOCKS ON THE MOVE-Qnity, J.M. Smucker, Vistra
Sarepta falls on bigger-than-expected Q4 loss
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite